NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Rating of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been given a consensus rating of “Moderate Buy” by the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $47.00.

NAMS has been the subject of a number of research analyst reports. Stifel Nicolaus upped their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Royal Bank Of Canada increased their price objective on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. The Goldman Sachs Group boosted their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research note on Tuesday, December 2nd. Finally, Needham & Company LLC upped their price target on NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $33.25, for a total transaction of $199,500.00. Following the sale, the insider directly owned 73,481 shares of the company’s stock, valued at $2,443,243.25. The trade was a 7.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Louise Frederika Kooij sold 75,117 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57. Following the completion of the transaction, the chief accounting officer owned 15,000 shares of the company’s stock, valued at $543,150. The trade was a 83.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 298,647 shares of company stock valued at $10,236,050 in the last 90 days. 20.84% of the stock is currently owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arizona State Retirement System boosted its position in NewAmsterdam Pharma by 3.8% during the third quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after purchasing an additional 483 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of NewAmsterdam Pharma by 2.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock worth $408,000 after purchasing an additional 521 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of NewAmsterdam Pharma by 5.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after purchasing an additional 544 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of NewAmsterdam Pharma by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after buying an additional 662 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $31.44 on Friday. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -15.34 and a beta of 0.07. The business has a 50 day simple moving average of $35.20 and a 200 day simple moving average of $31.25. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $4.54 million. On average, analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.